Philip Morris’ biopharmacy addiction escalates, as its’ Beyond Nicotine ‘platform sees it seize heart attack biotechnology OtiTopic

Philip Morris began selling tobacco products to the public in 1847, but, over 170 years later, the company read the tea leaves and saw that the future was “smoke-free”.

It’s bad enough for his business (although he still makes around $ 28 billion a year), and his business has proven to be pretty bad for the health of his customers, so the new idea is to help people. suffering from lung and heart diseases such as those caused by smoking.

Bitterly ironic? Maybe, but Philip Morris puts his money where his mouth is: This summer, he put $ 1.45 billion on the table for inhaled drug maker Vectura (although it isn’t going well), and now he is looking to diversify further with a new business to buy OtiTopic.

The US Respiratory Drug Development Company offers advanced-stage inhalable acetylsalicylic acid (ASA) therapy specifically designed for acute myocardial infarction, also known as a heart attack, for people at intermediate to high risk of myocardial infarction.

Inhalation therapy, known as Aspirhale, works like an inhalation of dry ASA powder delivered by a new self-administered aerosol.

He hopes to complete testing as soon as possible and, with the power of Philips behind him, file for FDA approval next year.

Early studies showed that the inhaled system “catalyzed peak plasma concentration and the desired pharmacodynamic effect, i.e. inhibition of platelet aggregation in two minutes versus 20 minutes for coated chewable aspirin. The company said in a statement.

“This speed is unprecedented and has significant potential implications for improving the survival of patients at risk of heart attack,” he added.

No financial condition has been included for the agreement.

“This transaction aligns well with OtiTopic’s goals of unlocking what we believe to be a significant opportunity in inhalation therapy science,” said Kambiz Yadidi, CEO of OtiTopic.

“We are entering into this transaction to expedite Aspirhale’s filing with the FDA, with the goal of providing innovative therapies to people at intermediate to high risk of myocardial infarction. “

For his part, Philip Morris is pursuing a so-called “Beyond Nicotine” strategy to extend cigarettes to areas such as respiratory medication administration and “personal well-being”. He is banking on this strategy to generate at least $ 1 billion in net income by 2025, CEO Jacek Olczak said in a statement a few weeks ago.

“In the United States alone, a person has a heart attack every 40 seconds. With its inhalable version of acetylsalicylic acid (ASA), OtiTopic has developed an active ingredient that promises to have a much faster effect than oral ASA, ”said Jorge Insuasty, Director of Life Sciences at Philip Morris.

“With its acquisition of OtiTopic, PMI looks forward to completing Aspirhale’s planned registration program and commercializing this important treatment to address a significant unmet medical need in a clinical condition where every second counts. “

According to the American Heart Association, cardiovascular disease, which can cause heart attacks, accounts for about 800,000 deaths in the United States each year, making it the leading cause of all deaths in the United States. Of these, nearly 20% are due to smoking, according to the FDA.

Philip Morris pledged to become more of a life science company and eventually stop selling cigarettes; however, he looks a bit like an arsonist selling fire damage insurance.

About Rhonda Lee

Check Also

New survey aims to track addiction recovery resources in Indiana

Indiana Family and Social Services Administration’s Mental Health and Addiction Division plans to use new …

Leave a Reply

Your email address will not be published.